LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments The…
The shares of health insurers in the U.S. recorded gains after the Trump administration announced 2027 payment rate increases for Medicare Advantage that were higher than…
Cancer research often relies on massive and complex datasets, which can take time and effort to sift through manually. The…
Researchers at the University of Calgary in Canada are conducting further trials after early studies revealed that vitamin B3, or niacin, holds…
According to a poll conducted by Gallup in March, Americans are most concerned about healthcare. This finding is notable given the…
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising. The company has appointed Chilean drug…
A recently published report by Mordor Intelligence analyzes future projections, growth drivers and the key trends that are shaping the…
Publishing research in peer-reviewed journals plays a central role in ensuring the credibility and reliability of scientific findings. Companies that…
LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”). LB-100 helps in…
A team of scientists from Texas Children’s Hospital, University of Pittsburgh and Baylor College of Medicine has discovered the primary driver of…